# **BC Cancer Protocol Summary for Treatment of Malignant Mesothelioma with Vinorelbine**

Protocol Code: LUMMVIN

**Tumour Group:** Lung

Contact Physician: Dr. Christopher Lee

#### **ELIGIBILITY:**

- First-line treatment in individuals not candidates for platinum-based combination chemotherapy
- Second-line treatment in individuals previously treated with platinum-based combination chemotherapy

#### **EXCLUSIONS:**

More than one previous chemotherapy regimen

## TESTS:

- Baseline: CBC & differential, platelets, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH
- Before each treatment: CBC & differential, platelets
- If clinically indicated: creatinine, bilirubin prior to each cycle

## PREMEDICATIONS:

- See antiemetic guidelines for Rare emetogenic chemotherapy (see protocol SCNAUSEA). Antiemetics are not usually required. Prescribe according to patient specific symptoms.
- Hydrocortisone 100mg IV prior to vinorelbine if patient experiences pain on administration

## TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
Vinorelbine	30 mg/m <sup>2</sup> /day on days 1 and 8	IV in 50 mL NS over 6 minutes

## Repeat every 21 days x 6 cycles

## **DOSE MODIFICATIONS:**

# 1. Hematological:

ANC (x 10 <sup>9</sup> /L)		Platelets (x 10 <sup>9</sup> /L)	Vinorelbine Dose*
greater than or equal to 1.0	and	greater than or equal to 100	100%
0.5 to less than 1.0	or	75 to less than 100	75%
less than 0.5	or	less than 75	Delay

<sup>\*</sup>Consider decreasing vinorelbine to 75% or 22.5mg/m² if an episode of febrile neutropenia occurs with the prior cycle of treatment

## 2. Hepatic dysfunction:

Bilirubin (micromol/L)	Vinorelbine Dose	
less than or equal to 35	100%	
36-50	50%	
greater than 50	25%	

## **PRECAUTIONS:**

- Extravasation: Vinorelbine causes pain and tissue necrosis if extravasated. It is recommended to flush thoroughly with 75-125 mL NS after infusing vinorelbine. Hydrocortisone 100mg IV prior to vinorelbine may be of benefit. Refer to BC Cancer Extravasation Guidelines.
- 2. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively.

Call Dr. Christopher Lee or tumour group delegate at (604) 877-6000 with any problems or questions regarding this treatment program.

## **REFERENCES:**

- 1. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18: 3912-7.
- 2. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-94.
- Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2008; in press (doi:10.1016/j.lungcan.2008.04.001).